erbitux produces benefit in study chicago the drug erbitux produced a modest improvement in a measure of survival in colorectal cancer patients when used as a first line treatment with chemotherapy according to a new study erbitux is co marketed in north america by imclone systems inc and bristol myers squibb co and outside north america by merck kgaa of germany results of the merck sponsored study were released in conjunction with the annual meeting of the american society of clinical oncology in chicago 
